Antibiotic use from formal and informal healthcare providers in the Democratic Republic of Congo: a population-based study in two health zones.

Anti-bacterial agents/therapeutic use/Antibiotic use Antibiotic resistance Antimicrobial resistance Antimicrobial stewardship Cross-sectional studies Democratic Republic of the Congo Developing countries Healthcare utilization

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 19 10 2021
revised: 14 03 2022
accepted: 03 04 2022
pubmed: 22 4 2022
medline: 20 9 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

In the Democratic Republic of Congo and other low-resource countries, community-acquired pathogens are increasingly resistant to most locally available antibiotics. To guide efforts to optimize antibiotic use to limit antibiotic resistance, we quantified healthcare provider-specific and community-wide antibiotic use. From household surveys, we estimated monthly healthcare visit rates by provider. From healthcare visit exit surveys, we estimated prevalence, defined daily doses, and access/watch/reserve distribution of antibiotic use by provider. Combining both, we estimated community-wide antibiotic use rates. Of 88.7 (95% CI 81.9-95.4) healthcare visits per 1000 person-months (n = 31221), visits to private clinics (31.0, 95% CI 30.0-32.0) and primary health centres (25.5, 95% CI 24.6-26.4) were most frequent. Antibiotics were used during 64.3% (95% CI 55.2-73.5%, 162/224) of visits to private clinics, 51.1% (95% CI 45.1-57.2%, 245/469) to health centres, and 48.8% (95% CI 44.4-53.2%, 344/454) to medicine stores. Antibiotic defined daily doses per 1000 inhabitants per day varied between 1.75 (95% CI 1.02-2.39) in rural Kimpese and 10.2 (95% CI 6.00-15.4) in (peri) urban Kisantu, mostly explained by differences in healthcare utilisation (respectively 27.8 versus 105 visits per 1000 person-months), in particular of private clinics (1.23 versus 38.6 visits) where antibiotic use is more frequent. The fraction of Watch antibiotics was 30.3% (95% CI 24.6-35.9%) in private clinics, 25.6% (95% CI 20.2-31.1%) in medicine stores, and 25.1% (95% CI 19.0-31.2%) in health centres. Treatment durations <3 days were more frequent at private clinics (5.3%, 9/169) and medicine stores (4.1%, 14/338) than at primary health centres (1.8%, 5/277). Private healthcare providers, ubiquitous in peri-urban settings, contributed most to community-wide antibiotic use and more frequently dispensed Watch antibiotics and shortened antibiotic courses. Efforts to optimize antibiotic use should include private providers at community level.

Identifiants

pubmed: 35447342
pii: S1198-743X(22)00205-1
doi: 10.1016/j.cmi.2022.04.002
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1272-1277

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Brecht Ingelbeen (B)

Institute of Tropical Medicine (ITM), Antwerp, Belgium; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: bingelbeen@itg.be.

Delphin M Phanzu (DM)

Kimpese Health Research Center, Kimpese, Democratic Republic of Congo.

Marie-France Phoba (MF)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Service of Microbiology, Department of Medical Biology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of Congo.

Mi Y N Budiongo (MYN)

Kimpese Health Research Center, Kimpese, Democratic Republic of Congo.

Neamin M Berhe (NM)

Institute of Tropical Medicine (ITM), Antwerp, Belgium.

Frédéric K Kamba (FK)

Kimpese Health Research Center, Kimpese, Democratic Republic of Congo; Centre de Coordination, de Recherches et de documentation en Sciences Sociales desservant L'Afrique Subsaharienne (CERDAS), Faculté des Sciences Sociales, Administratives et Politiques, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.

Lisette Kalonji (L)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Service of Microbiology, Department of Medical Biology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of Congo.

Bijou Mbangi (B)

Kimpese Health Research Center, Kimpese, Democratic Republic of Congo.

Liselotte Hardy (L)

Institute of Tropical Medicine (ITM), Antwerp, Belgium.

Bieke Tack (B)

Institute of Tropical Medicine (ITM), Antwerp, Belgium.

Justin Im (J)

International Vaccine Institute, Seoul, Republic of Korea.

Leonardo W Heyerdahl (LW)

Anthropology & Ecology of Disease Emergence Unit, Institut Pasteur, Paris, France.

Raquel Inocencio Da Luz (RI)

Institute of Tropical Medicine (ITM), Antwerp, Belgium.

Marc J M Bonten (MJM)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Octavie Lunguya (O)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Service of Microbiology, Department of Medical Biology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of Congo.

Jan Jacobs (J)

Institute of Tropical Medicine (ITM), Antwerp, Belgium; Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Placide Mbala (P)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.

Marianne A B van der Sande (MAB)

Institute of Tropical Medicine (ITM), Antwerp, Belgium; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH